Chronic Inflammatory Rheumatism, Rheumatoid Arthritis, Sjogren's Syndrome, Spondyloarthritis, Systemic Autoimmune Disease, Systemic Lupus Erythematosus
Conditions
Keywords
leukocytes, macrophages, lymphocytes, rare systemic autoimmune diseases, chronic inflammatory rheumatism
Brief summary
Exploration of pathophysiological mechanisms in chronic inflammatory rheumatism and rare systemic autoimmune diseases with the objective of identifying therapeutic targets.
Detailed description
The primary objective is to characterization of the quantitative and qualitative specificities of the different leukocyte sub-populations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases. We will perform an exploratory descriptive study whom primary endpoint will be to assess by FACS the phenotype of the specific leukocyte subsets. In addition, we will characterize the protein and transcriptomic signature associated with the conditions for which we have obtained preliminary data showing their potential involvement in autoimmunity (i.e: IL7 pathway, IFN signature).
Interventions
OTHERblood sample
sampling of blood for research during routine care
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Patient who did not express his opposition * Patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases (pSS, lupus, scleroderma, myositis, unclassified connectivitis) diagnosed according to the usual criteria. * Weight\> 35 kg
Exclusion criteria
* Corticosteroid treatment\> 10 mg / day * Pregnant patient * Patients under legal protection * Beneficiary of the state medical aid
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of the quantitative and qualitative specificities of the different leukocyte subpopulations in patients with chronic inflammatory rheumatism and rare systemic autoimmune diseases | At the end of the study (5 years) | Proportion of different leukocytes subset |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Protein study (ELISA on serum) : IL7 | At the end of the study (5 years) | levels of IL7 and other cytokines |
| Transcriptome study (RNA) : mRNA levels | At the end of the study (5 years) | assessement of different mRRNA involved in Il7/IFN pathways by molecular biology techniques (RNAseq, qPCR, nano string) |
| Genomic study (DNA) : SNPs | At the end of the study (5 years) | Determination of the genotype of different SNPs involved in IL7/IFN pathways |
Countries
France
Contacts
Primary ContactXavier MARIETTE
Outcome results
None listed